Skip to content

Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.

Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00382707
Enrollment
15
Registered
2006-09-29
Start date
2006-05-31
Completion date
2011-08-31
Last updated
2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Frontal Lobe Epilepsy

Keywords

repetitive transcranial magnetic stimulation, low frequency, frontal lobe epilepsy, brain excitability, electromyography

Brief summary

Epileptic disease is characterised by enhanced brain excitability. Low frequency repetitive transcranial magnetic stimulation (rTMS) can be an effective treatment for refractory frontal epilepsy. Thought, physiological mechanisms of its effectivity are still unknown. It is yet possible to evaluate cortical excitability and inhibition with TMS-coupled electromyography before and after rTMS sessions ; this could provide clues for basic mechanisms of rTMS effects on the epileptic brain. We assume that rTMS decrease brain excitability by improving brain inhibition. Such an information could help for treating patients with both pharmacological and non-pharmacological methods.

Interventions

DEVICEcortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cryptogenic frontal lobe epilepsy * Normal cerebral MRI

Design outcomes

Primary

MeasureTime frame
Electrophysiological parameters for cortical excitability measured just before and after rTMS, 4 hours later and 24 hours later.

Secondary

MeasureTime frame
Clinical efficacity on seizure intensity and frequency.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026